Developing the Next-Generation of Single & Dual Targeting siRNAs, Using DNA Nanotechnology

Time: 3:00 pm
day: Day One


  • As an alternative to standard 2’ chemical modification, we will discuss how DNA nanotechnology can be employed to confer critical therapeutic properties on siRNAs
  • These properties include tolerability and efficacy via stability to nuclease degradation and serum protein binding
  • Further important platform advantages of DNA-RNA hybrid agents include the potential for the short duration of target knockdown, facilitation of PK-PD studies, manufacturing, and scalability